Anti-HPV18 L1/Major capsid protein L1 Polyclonal Antibody

Catalog No.

PVV11803

Species reactivity

Human papillomavirus type 18

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant HPV18 L1/Major capsid protein L1 (Thr71-Lys568).

Tested applications

ELISA: 1:4000-1:8000, WB: 1:1000-1:4000

Target

L1 protein, L1

Purification

Purified by antigen affinity column.

Accession

NP_040317.1

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Human Papillomavirus and Thyroid Eye Disease., PMID:40272832

[A fluorescence immunochromatography method for detection of human papillomavirus type 16 E6 and L1 proteins]., PMID:39584350

A Novel Association Between Human Papillomavirus and Thyroid Eye Disease., PMID:38746201

Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination., PMID:36922512

Serologic Response to Human Papillomavirus Genotypes Among Unvaccinated Women: Findings From the HITCH Cohort Study., PMID:36322543

RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer., PMID:35703545

Designing of DNA Vaccine Based on a Secretory Form of Major Capsid Protein of Human Papillomavirus Type 18., PMID:34664812

The Synthesis of Main Capsid Protein of Anogenital Type HPV6 L1 in Plant Expression System on the Basis of Tomato Fruits., PMID:34189649

Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency., PMID:33636291

Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP., PMID:33573433

Identification of the mimotopes within the major capsid protein L1 of human papillomavirus types 18 and 45, using neutralizing monoclonal antibodies., PMID:33493568

Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists., PMID:33309485

Phylogeny and In Silico Structure Analysis of Major Capsid Protein (L1) Human Papillomavirus 45 from Indonesian Isolates., PMID:32986347

Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes., PMID:32967963

Simultaneous quantification of major capsid protein of human papillomavirus 16 and human papillomavirus 18 in multivalent human papillomavirus vaccines by liquid chromatography-tandem mass spectrometry., PMID:32067760

Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity., PMID:30560935

Epitope clustering analysis for vaccine-induced human antibodies in relationship to a panel of murine monoclonal antibodies against HPV16 viral capsid., PMID:30287156

Development and characterization of an HPV18 detection kit using two novel HPV18 type-specific monoclonal antibodies., PMID:30115088

L1 Recombinant Proteins of HPV Tested for Antibody Forming Using Sera of HPV Quadrivalent Vaccine., PMID:29984037

A Dual-Type L2 11-88 Peptide from HPV Types 16/18 Formulated in Montanide ISA 720 Induced Strong and Balanced Th1/Th2 Immune Responses, Associated with High Titers of Broad Spectrum Cross-Reactive Antibodies in Vaccinated Mice., PMID:29854852

Human papillomavirus 16L1-58L2 chimeric virus-like particles elicit durable neutralizing antibody responses against a broad-spectrum of human papillomavirus types., PMID:28968993

Immunization of mice by a multimeric L2-based linear epitope (17-36) from HPV type 16/18 induced cross reactive neutralizing antibodies., PMID:28855937

Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine., PMID:28736197

Development of a simple and quick immunochromatography method for detection of anti-HPV-16/-18 antibodies., PMID:28158224

The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies., PMID:28004837

Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles., PMID:27147749

Characterization of serum antibodies from women immunized with Gardasil: A study of HPV-18 infection of primary human keratinocytes., PMID:27113165

Observations on the expression of human papillomavirus major capsid protein in HeLa cells., PMID:26064080

Seroprevalence of 10 human papillomavirus types in the general rural population of Anyang, China: a cross-sectional study., PMID:25999521

Development of chimeric candidate vaccine against HPV18: a proof of concept., PMID:25929429

A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types., PMID:25790098

HIV is an important risk factor for human papillomavirus types 16 and 18 seropositivity among sexually active men who have sex with men., PMID:25668644

Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins., PMID:25203446

Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines., PMID:23722024

Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation., PMID:23536912

Detection of HPV E7 oncoviral protein in cervical lesions by a new antibody., PMID:22935825

Human papillomavirus (HPV) L1 and L1-L2 virus-like particle-based multiplex assays for measurement of HPV virion antibodies., PMID:22761294

Development of bead-based immunoassay to quantify neutralizing antibody for human papillomavirus 16 and 18., PMID:22669586

Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice., PMID:22561312

Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers., PMID:22438987

Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice., PMID:22426329

InterSCOPE study: Associations between esophageal squamous cell carcinoma and human papillomavirus serological markers., PMID:22228147

Capsomer vaccines protect mice from vaginal challenge with human papillomavirus., PMID:22069498

Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles., PMID:21803095

Genetic variability in the major capsid L1 protein of human papillomavirus type 16 (HPV-16) and 18 (HPV-18)., PMID:21729769

Cross-neutralization potential of native human papillomavirus N-terminal L2 epitopes., PMID:21346798

Papillomavirus capsid proteins mutually impact structure., PMID:21329956

The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay., PMID:21307649

Seroprevalence and determinants of eight high-risk human papillomavirus types in homosexual men, heterosexual men, and women: a population-based study in Amsterdam., PMID:20729796

Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies., PMID:20334659

Document Download

Anti-HPV18 L1/Major capsid protein L1 Polyclonal Antibody.pdf